Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
MXCT MaxCyte
5.430
-0.650-10.69%
Post Mkt Price
5.4300.0000.00%
YOY
Do not show
Hide blank lines
(Q3)2022/09/30(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31
Total revenue
4.97% 10.64M 35.17% 9.61M 78.41% 11.59M 29.52% 33.89M
Operating revenue
4.97% 10.64M 35.17% 9.61M 78.41% 11.59M 29.52% 33.89M
Cost of revenue
45.04% 1.37M 42.82% 1.12M 53.31% 1.06M 31.82% 3.65M
Gross profit
0.85% 9.27M 34.22% 8.49M 81.40% 10.52M 29.25% 30.25M
Operating expense
45.95% 16.99M 60.38% 17.23M 20.61% 14.68M 40.56% 48.44M
Selling and administrative expenses
23.55% 10.95M 59.69% 12.03M 80.94% 10.47M 89.53% 31.68M
-Selling and marketing expense
40.33% 4.51M 69.27% 4.93M 37.63% 3.84M 56.12% 13M
-General and administrative expense
14.02% 6.44M 53.66% 7.1M 121.24% 6.63M 122.72% 18.68M
Research and development costs
91.91% 5.33M 46.50% 4.7M -38.03% 3.77M -13.17% 15.41M
Depreciation amortization depletion
-- 709.8K -- 497.1K 43.55% 447.3K -- 1.35M
-Depreciation and amortization
-- 709.8K -- 497.1K 43.55% 447.3K -- 1.35M
Operating profit
-215.69% -7.71M -97.84% -8.74M 34.74% -4.16M -64.50% -18.19M
Net non-operating interest income expense
638.27% 1.28M 10,506.52% 478.7K 112.53% 91.8K -17.63% -893.6K
Non-operating interest income
2,607.57% 1.39M 5,466.28% 478.7K 836.73% 91.8K 128.83% 150.8K
Non-operating interest expense
-59.86% 116K -- 0 -- 0 26.50% 1.04M
Other net income (expense)
Income before tax
-140.03% -6.43M -86.81% -8.26M 42.76% -4.07M -61.49% -19.08M
Income tax
Net income
-140.03% -6.43M -86.81% -8.26M 42.76% -4.07M -61.49% -19.08M
Net income continuous Operations
-140.03% -6.43M -86.81% -8.26M 42.76% -4.07M -61.49% -19.08M
Minority interest income
Net income attributable to the parent company
-140.03% -6.43M -86.81% -8.26M 42.76% -4.07M -61.49% -19.08M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-140.03% -6.43M -86.81% -8.26M 42.76% -4.07M -61.49% -19.08M
Basic earnings per share
-100.00% -0.06 -60.00% -0.08 55.56% -0.04 -23.53% -0.21
Diluted earnings per share
-100.00% -0.06 -60.00% -0.08 55.56% -0.04 -23.53% -0.21
Dividend per share
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
------Unqualified Opinion

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. Its propriety cell therapy is used in drug discovery and development, and biomanufacturing. Its products include ATx, STx, and GTx instruments. The company was founded by Douglas A. Doerfler on July 31, 1998 and is headquartered in Rockville, MD.
CEO: Mr. Douglas Arthur Doerfler
Market: NASDAQ
Listing Date: 07/30/2021
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist